Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Areberg

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|May 1, 2021
Cytochrome P450 2D6 genotype-phenotype characterization through population pharmacokinetic modeling of tedatioxetineTrine Frederiksen, Johan Areberg, Ellen Schmidt, et al.
International Clinical Psychopharmacology|May 17, 2019
Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled studyEduard Vieta, Ioana Florea, Simon Nitschky Schmidt, et al.
Clinical Pharmacokinetics|June 14, 2021
Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring DataTrine Frederiksen, Robert L Smith, Birgit M Wollmann, et al.
Journal of Psychopharmacology (Oxford, England)|August 9, 2015
Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy menSue Wilson, Astrid-Maria Højer, Jeppe Buchberg, et al.
Headache|May 30, 2025
Pharmacokinetics and safety of eptinezumab in children and adolescents with migraineAndrew D Hershey, Johan Areberg, Line Pickering Boserup, et al.
Chest|October 16, 2002
Nutritional status and muscle strength in patients with emphysema and severe alpha(1)-antitrypsin deficiencyEeva Piitulainen, Johan Areberg, Mikael Lindén, et al.
Journal of Psychopharmacology (Oxford, England)|December 21, 2023
Clinical benefits and bioequivalence of vortioxetine oral drop solution versus oral tabletsAndrea Fagiolini, Michael Adair, Kamilla Buchberg Petersen, et al.
The AAPS Journal|April 6, 2006
The pharmacokinetics of escitalopram in patients with hepatic impairmentJohan Areberg, Jacob Strøyer Christophersen, Mette Nøhr Poulsen, et al.
Clinical Pharmacology and Therapeutics|November 9, 2022
Estimating the In Vivo Function of CYP2D6 Alleles through Population Pharmacokinetic Modeling of BrexpiprazoleTrine Frederiksen, Johan Areberg, Arash Raoufinia, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 16, 2006
Comparative renal, hepatic, and bone marrow toxicity of Cisplatin and radioactive Cisplatin (191Pt) in Wistar ratsKristina Norrgren, Maria Sjölin, Sven Björkman, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
CPT: Pharmacometrics & Systems Pharmacology|May 1, 2021
Cytochrome P450 2D6 genotype-phenotype characterization through population pharmacokinetic modeling of tedatioxetineTrine Frederiksen, Johan Areberg, Ellen Schmidt, et al.
International Clinical Psychopharmacology|May 17, 2019
Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled studyEduard Vieta, Ioana Florea, Simon Nitschky Schmidt, et al.
Clinical Pharmacokinetics|June 14, 2021
Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring DataTrine Frederiksen, Robert L Smith, Birgit M Wollmann, et al.
Journal of Psychopharmacology (Oxford, England)|August 9, 2015
Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy menSue Wilson, Astrid-Maria Højer, Jeppe Buchberg, et al.
Headache|May 30, 2025
Pharmacokinetics and safety of eptinezumab in children and adolescents with migraineAndrew D Hershey, Johan Areberg, Line Pickering Boserup, et al.
Chest|October 16, 2002
Nutritional status and muscle strength in patients with emphysema and severe alpha(1)-antitrypsin deficiencyEeva Piitulainen, Johan Areberg, Mikael Lindén, et al.
Journal of Psychopharmacology (Oxford, England)|December 21, 2023
Clinical benefits and bioequivalence of vortioxetine oral drop solution versus oral tabletsAndrea Fagiolini, Michael Adair, Kamilla Buchberg Petersen, et al.
The AAPS Journal|April 6, 2006
The pharmacokinetics of escitalopram in patients with hepatic impairmentJohan Areberg, Jacob Strøyer Christophersen, Mette Nøhr Poulsen, et al.
Clinical Pharmacology and Therapeutics|November 9, 2022
Estimating the In Vivo Function of CYP2D6 Alleles through Population Pharmacokinetic Modeling of BrexpiprazoleTrine Frederiksen, Johan Areberg, Arash Raoufinia, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 16, 2006
Comparative renal, hepatic, and bone marrow toxicity of Cisplatin and radioactive Cisplatin (191Pt) in Wistar ratsKristina Norrgren, Maria Sjölin, Sven Björkman, et al.
Pageof 3